drugset / Trial / NCT00389090

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

NCT00389090

Phase 2 Terminated 32 enrolled Keryx / AOI Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, phase II trial, assessing the antitumor activity, and safety of temozolomide in combination with O6-BG in patients with temozolomide-resistant anaplastic glioma.

Timeline

Start
2006-10
Primary completion
2008-06
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject O6-benzylguanine Small molecule Intravenous
Subject Temozolomide Small molecule